vs
Ginkgo Bioworks Holdings, Inc.（DNA）与FIRST UNITED CORP（FUNC）财务数据对比。点击上方公司名可切换其他公司
Ginkgo Bioworks Holdings, Inc.的季度营收约是FIRST UNITED CORP的1.4倍（$33.4M vs $23.2M），FIRST UNITED CORP同比增速更快（11.9% vs -23.8%），FIRST UNITED CORP自由现金流更多（$15.4M vs $-47.7M），过去两年FIRST UNITED CORP的营收复合增速更高（11.5% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
联合啤酒控股有限公司（又称UB集团）是喜力集团旗下的印度子公司，总部位于卡纳塔克邦班加罗尔的UB城。公司核心业务涵盖酒类饮品生产及多领域投资，是印度最大的啤酒生产商，主打以翠鸟为品牌的啤酒产品，同时拥有多款其他酒类品牌。
DNA vs FUNC — 直观对比
营收规模更大
DNA
是对方的1.4倍
$23.2M
营收增速更快
FUNC
高出35.7%
-23.8%
自由现金流更多
FUNC
多$63.1M
$-47.7M
两年增速更快
FUNC
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $23.2M |
| 净利润 | — | $5.8M |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 32.9% |
| 净利率 | — | 24.9% |
| 营收同比 | -23.8% | 11.9% |
| 净利润同比 | — | -6.6% |
| 每股收益（稀释后） | $-1.41 | $0.89 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNAFUNC
| Q4 25 | $33.4M | $23.2M | ||
| Q3 25 | $38.8M | $22.7M | ||
| Q2 25 | $49.6M | $21.8M | ||
| Q1 25 | $48.3M | $20.9M | ||
| Q4 24 | $43.8M | $20.8M | ||
| Q3 24 | $89.0M | $20.3M | ||
| Q2 24 | $56.2M | $20.1M | ||
| Q1 24 | $37.9M | $18.7M |
净利润DNAFUNC
| Q4 25 | — | $5.8M | ||
| Q3 25 | $-80.8M | $6.9M | ||
| Q2 25 | $-60.3M | $6.0M | ||
| Q1 25 | $-91.0M | $5.8M | ||
| Q4 24 | — | $6.2M | ||
| Q3 24 | $-56.4M | $5.8M | ||
| Q2 24 | $-217.2M | $4.9M | ||
| Q1 24 | $-165.9M | $3.7M |
营业利润率DNAFUNC
| Q4 25 | -211.9% | 32.9% | ||
| Q3 25 | -231.8% | 40.6% | ||
| Q2 25 | -132.1% | 36.5% | ||
| Q1 25 | -184.1% | 36.8% | ||
| Q4 24 | -236.3% | 39.2% | ||
| Q3 24 | -62.0% | 38.0% | ||
| Q2 24 | -396.7% | 32.5% | ||
| Q1 24 | -469.1% | 26.0% |
净利率DNAFUNC
| Q4 25 | — | 24.9% | ||
| Q3 25 | -207.9% | 30.6% | ||
| Q2 25 | -121.6% | 27.5% | ||
| Q1 25 | -188.2% | 27.7% | ||
| Q4 24 | — | 29.8% | ||
| Q3 24 | -63.3% | 28.5% | ||
| Q2 24 | -386.4% | 24.5% | ||
| Q1 24 | -437.3% | 19.8% |
每股收益（稀释后）DNAFUNC
| Q4 25 | $-1.41 | $0.89 | ||
| Q3 25 | $-1.45 | $1.07 | ||
| Q2 25 | $-1.10 | $0.92 | ||
| Q1 25 | $-1.68 | $0.89 | ||
| Q4 24 | $-1.91 | $0.95 | ||
| Q3 24 | $-1.08 | $0.89 | ||
| Q2 24 | $-4.23 | $0.75 | ||
| Q1 24 | $-3.32 | $0.56 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $131.6M |
| 总债务越低越好 | — | $95.9M |
| 股东权益账面价值 | $508.6M | $203.6M |
| 总资产 | $1.1B | $2.1B |
| 负债/权益比越低杠杆越低 | — | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资DNAFUNC
| Q4 25 | $422.6M | $131.6M | ||
| Q3 25 | $495.5M | $95.2M | ||
| Q2 25 | $559.4M | $79.1M | ||
| Q1 25 | $325.3M | $84.4M | ||
| Q4 24 | $561.6M | $78.3M | ||
| Q3 24 | $616.2M | $62.4M | ||
| Q2 24 | $730.4M | $45.1M | ||
| Q1 24 | $840.4M | $86.9M |
总债务DNAFUNC
| Q4 25 | — | $95.9M | ||
| Q3 25 | — | $95.9M | ||
| Q2 25 | — | $120.9M | ||
| Q1 25 | — | $120.9M | ||
| Q4 24 | — | $120.9M | ||
| Q3 24 | — | $120.9M | ||
| Q2 24 | — | $70.9M | ||
| Q1 24 | — | $70.9M |
股东权益DNAFUNC
| Q4 25 | $508.6M | $203.6M | ||
| Q3 25 | $559.8M | $199.1M | ||
| Q2 25 | $613.0M | $191.1M | ||
| Q1 25 | $647.4M | $183.7M | ||
| Q4 24 | $716.1M | $179.3M | ||
| Q3 24 | $797.9M | $174.0M | ||
| Q2 24 | $833.1M | $164.2M | ||
| Q1 24 | $987.3M | $165.5M |
总资产DNAFUNC
| Q4 25 | $1.1B | $2.1B | ||
| Q3 25 | $1.2B | $2.0B | ||
| Q2 25 | $1.2B | $2.0B | ||
| Q1 25 | $1.3B | $2.0B | ||
| Q4 24 | $1.4B | $2.0B | ||
| Q3 24 | $1.5B | $1.9B | ||
| Q2 24 | $1.6B | $1.9B | ||
| Q1 24 | $1.6B | $1.9B |
负债/权益比DNAFUNC
| Q4 25 | — | 0.47× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.63× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | — | 0.67× | ||
| Q3 24 | — | 0.70× | ||
| Q2 24 | — | 0.43× | ||
| Q1 24 | — | 0.43× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $19.4M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $15.4M |
| 自由现金流率自由现金流/营收 | -142.8% | 66.3% |
| 资本支出强度资本支出/营收 | 0.0% | 17.1% |
| 现金转化率经营现金流/净利润 | — | 3.35× |
| 过去12个月自由现金流最近4个季度 | — | $22.7M |
8季度趋势，按日历期对齐
经营现金流DNAFUNC
| Q4 25 | $-47.7M | $19.4M | ||
| Q3 25 | $-31.6M | $1.5M | ||
| Q2 25 | $-40.3M | $995.0K | ||
| Q1 25 | $-51.5M | $7.0M | ||
| Q4 24 | $-42.4M | $22.3M | ||
| Q3 24 | $-103.5M | $2.3M | ||
| Q2 24 | $-84.4M | $7.2M | ||
| Q1 24 | $-89.3M | $3.6M |
自由现金流DNAFUNC
| Q4 25 | $-47.7M | $15.4M | ||
| Q3 25 | — | $168.0K | ||
| Q2 25 | $-40.3M | $706.0K | ||
| Q1 25 | $-59.1M | $6.4M | ||
| Q4 24 | $-56.1M | $20.4M | ||
| Q3 24 | $-118.6M | $588.0K | ||
| Q2 24 | $-111.4M | $7.0M | ||
| Q1 24 | $-96.0M | $3.5M |
自由现金流率DNAFUNC
| Q4 25 | -142.8% | 66.3% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | -81.2% | 3.2% | ||
| Q1 25 | -122.4% | 30.5% | ||
| Q4 24 | -128.0% | 98.1% | ||
| Q3 24 | -133.2% | 2.9% | ||
| Q2 24 | -198.2% | 35.1% | ||
| Q1 24 | -252.9% | 18.9% |
资本支出强度DNAFUNC
| Q4 25 | 0.0% | 17.1% | ||
| Q3 25 | 0.0% | 5.9% | ||
| Q2 25 | 0.1% | 1.3% | ||
| Q1 25 | 15.8% | 2.8% | ||
| Q4 24 | 31.3% | 9.3% | ||
| Q3 24 | 16.9% | 8.4% | ||
| Q2 24 | 48.1% | 0.6% | ||
| Q1 24 | 17.7% | 0.3% |
现金转化率DNAFUNC
| Q4 25 | — | 3.35× | ||
| Q3 25 | — | 0.22× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | — | 1.20× | ||
| Q4 24 | — | 3.60× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 1.46× | ||
| Q1 24 | — | 0.97× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
FUNC
| Trust Department | $9.8M | 42% |
| Other | $5.6M | 24% |
| Debit Card Income | $4.1M | 17% |
| Service Charges | $2.3M | 10% |
| Brokerage Commissions | $1.4M | 6% |
